I am curious as to what the authors, faculty members, and residents following this journal club think might change as a result of this study with regards to current clinical practice guideline recommendations for extended VTE therapy in patients not deemed at high risk for bleeding. Currently, the 2016 CHEST guidelines assign these grades for first unprovoked VTE in low risk bleed patients (2B=weak recommendation, moderate level of evidence), recurrent unprovoked VTE in low risk bleed patients (1B=strong recommendation, moderate evidence), and recurrent unprovoked VTE in medium risk bleed patients (2B=weak, moderate evidence). The size of effect demonstrated in this study for rivaroxaban vs. aspirin seems quite substantial in my opinion.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.